6‐[18F]Fluoro‐L‐DOPA probes dopamine turnover rates in central dopaminergic structures

Publisher Website
Google Scholar
Abstract
6‐[18F]Fluoro‐L‐DOPA (FDOPA) cerebral kinetics and metabolism were correlated in normal primates (Macaca nemestrina) and primates with 1‐methyl‐4‐phenyl‐l,2,3,6‐tetrahydropyridine (MPTP) induced unilateral Parkinsonism. Application of a tracer kinetic model to positron emission tomography (PET) data indicated that the model allows reliable estimation of FDOPA blood brain barrier transport, decarboxylation and release of stored 6‐[18F]fluorodopamine (FDA) radioactivity in normal striatum (k4 = 0.005/min, turnover half‐time ≥ 2 hr), in agreement with biochemical data. PET scans of MPTP treated monkeys revealed 40‐50% reduction in total striatal activity in comparison with pre‐MPTP scans. Monkey brain biochemical analysis revealed that the reduction in activity was mainly due to a decrease in FDA and its metabolites, 6[18F]fluorohomovanillic (FHVA) and 6‐[18F]fluoro‐3, 4‐dihydroxyphenylacetic acid (FDOPAC). The remaining activity in tissue was 3‐0‐methyl‐6‐[18F]fluoro‐L‐DOPA (3‐OMFD) of peripheral origin. The (FHVA + FDOPAc)/FDA ratio was 1:2 in normal putamen and ≥6:1 in the lesioned putamen, indicative of a dramatic increase in turnover of FDA. Both kinetic and biochemical data indicate that FDOPA labels a slow turnover rate pool of dopamine in rat and primate brain. This turnover rate for stored dopamine (DA) is accelerated with dopaminergic cell losses (e.g., MPTP‐induccd Parkinsonism).

This publication has 27 references indexed in Scilit: